New survey finds that most PCPs screen for mild cognitive impairment, but time is an issue, guidelines are few, and low levels of confidence persist.

As adjunctive treatment, lumateperone is associated with early symptom improvement, good tolerability, and provides a practical no-titration option for adults with persistent MDD.

Novo Nordisk’s STEP UP trial shows semaglutide delivers 21% weight loss and reduces key cardiovascular and metabolic risk factors in obesity management.

New longitudinal data from a Korean cohort suggest OSA may be an independent risk factor for cerebral small vessel disease.

Novel AD therapies targeting OX40, IL-13, IL-36, IL-22, and IL-2 pathways show promise for disease modification and extended dosing intervals in phase 2-3 trials.

Global survey data highlight persistent stigma and self-management barriers for adults with diabetes in the workplace, with implications for clinical care.

The FDA approves a single monthly injection of mirikizumab-mrkz for ulcerative colitis, enhancing patient convenience and addressing bowel urgency effectively.

Patient preferences favor home-based tests but MDs do not, while cost barriers significantly impact follow-up completion, according to the 2 new analyses.

These 42 factors that affect blood glucose are in categories including food, activity, and biological influences. Perfect information to share with your patients with T2D.

Panelists discuss how vasomotor symptoms undermine physical comfort, sleep, and long-term health, emphasizing integrative management to restore overall quality of life.

Panelists discuss how hormonal decline and KNDy neuron overactivation drive vasomotor symptoms and inform the development of targeted neurokinin receptor therapies.